Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using fully human monoclonal antibodies to treat life-threatening infectious diseases. Its lead product candidate, AR-301, is a fully human immunoglobulin G1 monoclonal antibody that has completed Phase III pivotal trials for lung infections caused by Staphylococcus aureus alpha-toxin and is being developed as an adjunctive therapy with standard-of-care antibiotics for hospital-acquired and ventilator-associated pneumonia. The company is also advancing AR-320, a monoclonal antibody targeting S. aureus alpha-toxin for infections from methicillin-resistant and susceptible strains; AR-501, an inhaled gallium citrate formulation in Phase 1/2a trials for chronic lung infections in cystic fibrosis patients; and AR-101, a human IgM monoclonal antibody in Phase II trials against Pseudomonas aeruginosa lipopolysaccharide serotype O11. Aridis Pharmaceuticals Inc. operates in the biotechnology sector, emphasizing novel anti-infective solutions for hospital and ventilator-related bacterial infections. Founded in 2003 and headquartered in Los Gatos, California, it remains dedicated to addressing unmet needs in infectious disease treatment.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Vu L. Truong Ph.D.

Employees

37

Headquarters

Los Gatos, CA, United States

Website

www.aridispharma.com